CALGB


Also found in: Acronyms.

CALGB

Cancer and Leukemia Group B. A national (US) clinical research group sponsored by the NCI, with its central office headquartered at the University of Chicago and its statistical centre located at Duke University.
References in periodicals archive ?
A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of CALGB.
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: A CALGB randomized trial of efficacy, quality of life and cost-effectiveness.
In its simplest sense, that is what the CALGB 9251 protocol is.
Publication in the New England Journal of Medicine of three phase III REVLIMID trials in newly diagnosed multiple myeloma (MM-015, IFM 2005-02, and CALGB 100104).
The CHMP recommendation was based on the results of two cooperative group-led studies, CALGB 10010410 and IFM 2005-0211:
Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712.
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Meyerhardt and his group published an analysis of data from a National Cancer Institute-sponsored study called CALGB 89803 that involved 1,264 patients with stage II colon cancer, randomized to treatment with 5-fluorouracil and leucovorin with or without irinotecan following surgical resection.
cyclophosphamide-epirubicin-fluorouracil)] and CALGB 8541 trials all demonstrated anthracycline sensitivity in HER2-amplified tumours.
The phase III CALGB 80405 trial in which patients are randomized to FOLFIRI/FOLFOX plus cetuximab or bevacizumab or cetuximab and bevacizumab [63] will hopefully answer this question and establish which targeted agent is the preferred combination partner.
The practice is affiliated with national Clinical Study protocol groups, CALGB,(Cancer and Leukemia Group B), and NSABP(National Surgical Adjuvant Breast and Bowel Project), offering patients the opportunity of national clinical studies, through The Vermont Regional Cancer Center.
The first of the studies, CALGB 8541, began accruing patients 20 years ago.